MAPK8 and cervical carcinoma: Caspase inhibitor z-VAD-fmk and p38 MAPK inhibitor BIRB796 significantly reversed CaSki and C33A cell growth and alleviated p38 MAPK activation in cells treated with metformin combined with everolimus (Figure 7), which can be explained by the fact that p38, ERK, and JNK promote human cervical cancer cell death by regulating metformin- and/or everolimus-induced cell apoptosis.